Little Green Pharma’s Cannatrek deal clears a regulatory haze, but shareholders still have the last word

Little Green Pharma’s proposed acquisition of Cannatrek has moved a step closer to the finish line, with the key regulatory overhang now looking more manageable than feared.

The company says Cannatrek has reached an in-principle agreement with the Therapeutic Goods Administration over alleged historical breaches of the Therapeutic Goods Act and related regulations. The matter relates to Cannatrek’s past advertising of therapeutic goods, a sensitive area for medicinal cannabis companies given the tight controls around promotion, patient access and compliant communications.

Importantly for LGP investors, the expected civil penalty is understood to sit within the economic parameters already built into the transaction. LGP does not yet know the exact quantum of the penalty, and it has stressed that the amount is material. However, the company believes it remains within the limits covered by the contingent value share, or CV Share, mechanism.

That distinction matters. The Cannatrek deal has always carried a regulatory wrinkle, and the CV Shares appear designed to stop unknown liabilities from landing too heavily on existing LGP shareholders. While the penalty is not immaterial, the market is likely to focus on the fact that the issue appears to have been ring-fenced rather than allowed to become a deal-breaker.

The $6.5 million kicker

Just as notable is Cannatrek’s expected capital contribution at completion. LGP says Cannatrek anticipates bringing an additional estimated $6.5 million of capital into the merged group above the minimum agreed under the transaction documents.

For a medicinal cannabis business, cash is not a cosmetic detail. The sector has been littered with companies that discovered too late that cultivation capacity, regulatory compliance, working capital, distribution and overseas expansion all require hard dollars rather than PowerPoint ambition.

An extra $6.5 million would provide the combined entity with a little more breathing room as it seeks to integrate operations and press its advantage in Australia and offshore markets. LGP already has vertically integrated operations across Australia and Europe, including production assets in Denmark and Australia. The company says it supplies medicinal cannabis products into Australia and more than 12 export markets, with positions in France, Germany and the UK.

The Cannatrek acquisition, if completed, would add further scale in a domestic market where brand presence, prescribing channels, product breadth and compliance discipline all matter.

Conditions precedent appear on track

LGP says the parties do not currently anticipate any issues satisfying the remaining conditions precedent to the scheme. That is another useful signal for investors watching the transaction timeline.

Schemes of arrangement are legal and procedural beasts, and even friendly deals can stall if conditions are not met, court approvals are delayed or shareholder support wobbles. The company’s message is that the machinery is still moving.

The next key event is the LGP general meeting, scheduled for 3.30pm Perth time on 22 May 2026. Shareholders will vote on the resolution to approve the issue of new LGP ordinary shares and new LGP CV Shares connected with the Cannatrek scheme consideration.

The board has unanimously recommended shareholders vote in favour of the resolution, provided no superior proposal emerges. Each LGP director also intends to vote any shares they control in favour of the resolution on the same basis.

A virtual vote with a tight timetable

The general meeting will be held virtually via Zoom. Shareholders who want to vote live at the meeting must notify the company secretary by 3.30pm Perth time on 20 May 2026. The voting eligibility record time is 5.00pm Perth time on the same day.

Proxy votes already submitted remain valid. Shareholders who have not voted, or who want to amend their vote, can do so electronically through the share registry before the proxy cut-off.

If shareholders approve the resolution and the remaining steps proceed as expected, the second court hearing is scheduled for 25 May 2026, with the scheme expected to become effective the same day. The implementation date, when consideration securities are due to be issued, is scheduled for 1 June 2026.

Why the update matters

For investors, this is less about medicinal cannabis glamour and more about transaction risk.

The TGA matter was the obvious loose thread. A material civil penalty is never welcome, but LGP’s view that it falls within the pre-agreed CV Share framework reduces the likelihood of a nasty surprise outside the negotiated deal economics. The additional capital expected from Cannatrek also helps the optics, particularly in a sector where balance sheet durability remains a recurring investor concern.

That said, the transaction is not yet complete. The penalty amount has not been disclosed, shareholders still need to vote, and court approval remains part of the process. Integration risk will also matter once the legal formalities are done.

For now, LGP has given investors a clearer read on the big regulatory question hanging over the Cannatrek acquisition. The answer is not entirely pain-free, but it looks containable. In medicinal cannabis, where the difference between growth story and cautionary tale often comes down to compliance and cash, that is no small thing.